Connors Investor Services’s Anika Therapeutics ANIK Stock Holding History

Connors Investor Services’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-14,403	Closed	-$216K	–	157
2025 Q1	$216K	Buy	14,403 +2,843	+25%	+$47.3K	0.02%	135
2024 Q4	$190K	Buy	11,560 +861	+8%	+$17K	0.02%	147
2024 Q3	$264K	Hold	10,699	–	–	0.03%	128
2024 Q2	$271K	Hold	10,699	–	–	0.03%	124
2024 Q1	$272K	Hold	10,699	–	–	0.03%	127
2023 Q4	$242K	Hold	10,699	–	–	0.03%	127
2023 Q3	$199K	Buy	10,699 +2,500	+30%	+$51.8K	0.02%	137
2023 Q2	$213K	Hold	8,199	–	–	0.02%	143
2023 Q1	$235K	Hold	8,199	–	–	0.03%	139
2022 Q4	$243K	Buy	+8,199	New	+$233K	0.03%	130
2022 Q1	–	Sell	-7,699	Closed	-$276K	–	162
2021 Q4	$276K	Buy	7,699 +1,500	+24%	+$60K	0.03%	131
2021 Q3	$264K	Hold	6,199	–	–	0.03%	137
2021 Q2	$268K	Buy	6,199 +500	+9%	+$21.3K	0.03%	137
2021 Q1	$232K	Buy	5,699 +1,000	+21%	+$37.9K	0.03%	141
2020 Q4	$213K	Buy	+4,699	New	+$178K	0.03%	131

Other funds holding ANIK

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AFA

Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return

Connors Investor Services's ANIK Position: Q2 2025 in Review

Connors Investor Services sold out of Anika Therapeutics (ANIK) in Q2 2025, closing a stake of 14,403 shares — an estimated $216K sold.

Connors Investor Services first reported a position in ANIK in Q4 2020 and held it in 15 quarters. The position peaked at $276K in Q4 2021. 103 funds tracked by Wall St. Rank hold ANIK as of Q2 2025.

Connors Investor Services reported no remaining Anika Therapeutics position as of Q2 2025 after selling out during the quarter.
Connors Investor Services sold 14,403 Anika Therapeutics shares in Q2 2025, an estimated $216K.
Connors Investor Services first reported a position in Anika Therapeutics in Q4 2020 and held it in 15 quarters.
Connors Investor Services's Anika Therapeutics position peaked at $276K in Q4 2021.
103 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2025.

Based on Connors Investor Services's 13F filing for Q2 2025, filed 30 Jul 2025.